News Category: Regulatory news
The HPRA would like to inform stakeholders that the Practical guidance for procedures related to Brexit for medicinal products for human use approved via MRP/DCP and the Practical guidance on the implementation of the Protocol on Ireland/Northern Ireland for medicinal products for human use approved via MRP/DCP have been updated/published on the CMDh website dated December 2020.
These documents reflect the current position for MRP/DCP products, and should be consulted in advance of submitting related Brexit queries to brexit@hpra.ie.